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A 54-year-old patient, with known history of 
type 1 diabetes mellitus and hypercholesterolemia 
had been referred to the documented center due 
to subacute non-ST segment elevation myocardial 
infarction. Coronary angiography revealed a high-
grade unstable and calcified lesion in the middle 
portion of the right coronary artery considered 
as a culprit lesion (Fig. 1A). The lesion prepara-
tion was achieved using a 2.5 × 15 mm compliant 
balloon inflated up to 14 atmospheres (atm), then 
a 3.0 × 15 mm non-compliant balloon inflated up to 
18 atm (3.12 mm); subsequently, a second-generation 
everolimus-eluting bioresorbable vascular scaffold 
(BVS, ABSORBTM 3.0 × 18 mm, Abbott Vascular, 
Santa Clara CA, USA) was deployed progressively 
up to 11 atm (3.24 mm). Optical frequency-domain 
imaging (OFDI, Ilumien Optis System from St. Jude 
Medical, Inc. St. Paul, MN, USA) were utilized to 
assess the strut apposition inapparent in coronary 
angiography (Fig. 1B–D). Overall, 183 cross-sec-
tions were evaluated during three OFDI-pullbacks 
(n = 1615 struts). Struts were malapposed when 
the distance of the adluminal strut reflection from 
the vessel wall exceeded half of the nominal strut 
thickness (75 out of 150 μm). Strut malapposition 
of 13.02% (n = 74/560) was documented direc- 
tly after BVS implantation (Fig. 1B, E), 8.70% 
(n = 46/529) after several post-dilatations with 
a 3.0 × 12 mm non-compliant balloon inflated 
up to 24 atm (3.20 mm) (Fig. 1C, F) and 6.10% 
(n = 32/525) after an additional two post-dilatations 
with a 3.5 × 15 mm non-compliant balloon inflated 
up to 14 atm (3.54 mm) (Fig. 1D, G).
This example case illustrates some impor-
tant procedural techniques for optimal implan-
tation of a BVS. A 1:1 balloon:vessel pre-dil-
atation was achieved (3.12 mm for a 3.0 mm 
BVS). Post-dilatation with a non-compliant balloon 
was performed afterwards and inflated 0.5 mm 
over the nominal diameter of the scaffold. Since 
BVS implant is radiolucent, additional intrac-
oronary imaging modalities i.e. OFDI are valu-
able to guide optimal BVS-strut apposition [1–3], 
which was very well demonstrated in this case, 
especially that post-dilatation strategies were 
oriented based on struts malapposition observed 
on OFDI consecutive pullbacks. It was observed 
that strut apposition significantly improved after 
further post-dilatations with higher pressure bal-
loons (13.02%, 8.70% to 6.10% progressively). 
At 30-days follow-up, the patient evolution was 
smooth and free of cardiovascular event.
The in-scaffold thrombosis is a major concern 
following BVS-implantation [4]. The impact of 
stent apposition and strut characteristics on the 
neointimal healing process and subsequent stent 
thrombosis are clearly demonstrated [5]. The impor-
tance of pre and post-dilatation in optimizing scaffold 
implantation and expansion should not be underes-
timated, particularly in the case of complex lesions 
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(i.e. bifurcations, long lesions, calcified plaques and 
acute coronary syndromes) [6] where BVS under-
expansion, and malapposition are considered main 
pathomechanisms for both sub-acute or late throm-
botic events [7, 8]. Additionally, post-dilatation after 
a BVS implantation seems to be beneficial even for 
soft lesions [9, 10]. On the other hand, it should be 
emphasized that balloon post-dilatation could result 
in BVS edge dissection or de-novo stenosis in case 
of “geographical miss” when the balloon markers are 
outside the scaffold markers during post-dilatation. 
Moreover, overexpansion of the scaffold could be 
also harmful and may result in strut fracture [11] 
or vessel perforation.
When reviewing the previous publications on 
BVS, we observe a fluctuation of post-dilatation 
rate, going from only 14% of cases in some series 
[12] to more than 60% [4, 13] and even up to 90% 
in other series [14]. 
Concerns about in-stent thrombosis exist and 
meticulous procedural techniques application i.e. 
pre and postdilatation as well as imaging guided 
percutaneous coronary intervention to optimize 
struts apposition may be beneficial in order to 
diminish this risk. Further studies are needed to 
better clarify this issue.
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Figure 1. Serial right coronary artery angiography images (A–D) and correspondent optical frequency-domain imag-
ing consecutive pullbacks (E–G). Panel A shows the culprit lesion of the right coronary artery. Panels B, E and the red 
squares show the results after bioresorbable vascular scaffold (BVS) implantation with 13.02% of strut malapposition. 
Panels C, F and the yellow squares show the results after the first postdilatation with a 3.0 × 12 mm non-compliant 
balloon with 8.70% of strut malapposition. Panels D, G and the blue squares show the final result after additional post-
dilatation with a 3.5 × 15 mm non-compliant balloon with 6.1% of residual strut malapposition; NC — non-compliant 
balloon.
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